The firm currently has a $44.20 price target on the stock. Zacks ' target price suggests a potential upside of 2.31% from the stock's previous close.
http://www.americanbankingnews.com/2013/08/08/vitamin-shoppe-upgraded-by-zacks-to-neutral-vsi/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+AmericanBankingNews+%28American+Banking+News%29
http://www.americanbankingnews.com/2013/08/08/vitamin-shoppe-upgraded-by-zacks-to-neutral-vsi/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+AmericanBankingNews+%28American+Banking+News%29
No comments:
Post a Comment